Aptevo Therapeutics Announces $4.5M Warrant/PIPE Financing

What Happened
Aptevo Therapeutics announced that it entered into warrant inducement letters and a Securities Purchase Agreement with certain holders, resulting in the issuance and sale of warrants and shares that generated approximately $4.5 million in aggregate gross proceeds (before fees and expenses). The transactions included the inducement of existing warrants to be exercised for cash and the private placement (PIPE) of shares and warrants. The deals closed on August 13, 2026; some new warrants (Inducement Warrants and Common Warrants) become exercisable only after the company obtains required stockholder approval, while Pre‑Funded Warrants are immediately exercisable.

Key Details

• Existing warrant exercises: holders agreed to exercise up to 254,922 existing warrants at $4.03 per share, yielding up to about $1.0 million of gross proceeds before fees/expenses.
• New securities issued: Inducement Warrants to buy up to 1,274,610 shares; PIPE included up to 861,708 shares (or pre‑funded warrants in lieu) and PIPE Common Warrants to buy up to 4,308,540 shares — all at $4.03 per share.
• Timing & registration: Company agreed to file a resale registration statement by August 22, 2026 and use commercially reasonable efforts to have it effective by September 26, 2026 (or October 26 if the SEC conducts a full review).
• Fees & closing: Roth Capital Partners served as exclusive placement agent and will receive a 7% placement fee plus reimbursement of up to $100,000 in legal expenses. Transactions closed August 13, 2026.

Why It Matters

• Cash and dilution: The financing provides near‑term cash (net proceeds for working capital/general corporate purposes) but also creates potential future dilution because millions of warrants were issued that could convert into common stock at $4.03 per share.
• Shareholder vote and timing: Many of the new warrants cannot be exercised until the company obtains stockholder approval, so the timing of any dilution depends on that vote and on the registration statement becoming effective.
• Investor impact: Retail investors should note the exercise price, the ownership caps (4.99% or 9.99% limits on exercise to prevent single‑party control), and the registration rights that allow holders to resell shares once the registration statement is effective.